THE URGENT NEED FOR BETTER LUNG DISEASE DIAGNOSTICS
Lung diseases cause millions of deaths every year. COPD alone ranks as the third deadliest disease worldwide, and lung cancer remains the most common and deadliest form of cancer.
Despite these alarming facts, researchers still lack effective, non-invasive tools to study lung health at the molecular level.
This gap in diagnostics slows the development of early detection methods and life-saving treatments, leaving millions of people worldwide struggling with undiagnosed or poorly monitored lung conditions.
Advancing non-invasive, precise, and accessible diagnostic solutions is critical to improving patient outcomes and transforming respiratory healthcare.
THE NEED FOR NON-INVASIVE SAMPLING
To save lives, we need to detect lung diseases earlier and treat them more effectively. However, traditional diagnostic methods—such as bronchoscopy and sputum analysis—can be invasive, uncomfortable, and unreliable for studying small airway changes.
A non-invasive, precise sampling and analysis solution would revolutionize respiratory research, enabling:
Early detection – Identifying biomarkers before symptoms appea
Disease monitoring – Understanding how lung conditions evolve over time.
Treatment assessment – Measuring how patients respond to therapies.
Exposure analysis – Investigating the impact of air pollution, allergens, and workplace hazards.
PExA: A STEP FORWARD IN PULMONARY SCIENCE
With PExA, scientists, researchers, and clinicians can explore the lungs like never before—analyzing exhaled airway particles to unlock critical molecular insights that lead to earlier diagnoses, better treatments and improved patient outcomes.
By enabling non-invasive, precise analysis of small airway particles, PExA makes lung research more accessible and data-driven, paving the way for breakthroughs in respiratory medicine.
Latest press releases
latest news